Multiple Myeloma

Therapeutic Rationale Trial Number Trial Description
Ruxolitinib* is an oral, selective inhibitor of JAK1 and JAK2 that is FDA approved for the treatment of intermediate and high-risk myelofibrosis and polycythemia rubra vera. Pilot experiments carried out in the Institute for Myeloma and Bone Cancer Research demonstrated that ruxolitinib, in combination with lenalidomide and dexamethasone, inhibited the proliferation of the multiple myeloma cell lines U266 and RPMI8226, and primary tumor cells derived from multiple myeloma patients. This inhibition was greater than that achieved with these drugs as single agents. Enhanced anti-tumor activity was also observed when these three drugs were administered together to immunodeficient mice bearing human multiple myeloma xenografts LAGk-1A (bortezomib/melphalan-sensitive) and LAGk-2 (bortezomib/melphalan-resistant). Ruxolitinib as a single agent showed no anti multiple myeloma effects whereas the combination of this drug with dexamethasone showed enhanced anti multiple myeloma effects compared to steroid treatment alone. Finally, an elderly and heavily pretreated multiple myeloma patient with polycythemia rubra vera, who had previously received single-agent ruxolitinib, progressed from monoclonal gammopathy of undetermined significance to multiple myeloma. He subsequently failed treatment with lenalidomide and methylprednisolone, but his multiple myeloma responded to the addition of low dose ruxolitinib administered twice daily with his two existing drugs. Together, these results suggest that ruxolitinib may overcome lenalidomide and steroid resistance for relapsed/refractory multiple myeloma patients that are failing therapy from steroids alone or in combination with lenalidomide. NCT03110822 A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Learn more at ›

Enrollment Status: Active, Recruiting


West Hollywood, California
Bakersfield, California
Encinitas, California
Fountain Valley, California
Monterey, California
Penbroke Pines, Florida

About Multiple Myeloma

Multiple myeloma is a form of blood cancer that occurs when white blood cells known as plasma cells, which are typically found in the bone marrow, grow out of control and develop into tumors. Approximately 30,000 new cases of multiple myeloma will be diagnosed this year in the U.S. There are few known risk factors for developing this disease and it may not cause signs or symptoms that would lead to a diagnosis until it has advanced to the kidneys and other organs. (Adapted from American Cancer Society, Cancer A – Z.)

* Ruxolitinib ( Jakafi® ) is marketed by Incyte. Lenalidomide ( Revlimid® ) is marketed by Celgene. OncoTracker has filed for patent protection on use of the combination of these two drugs with steroids to treat multiple myeloma patients.